



The Administrative Art of Supporting Clinical and Translational Health Research

Presented by Maria J. Hernandez, Ben Towne Center Business Operations Director



Seattle Children's®
HOSPITAL • RESEARCH • FOUNDATION

Research at Seattle Children's

Ben Towne Center for
Childhood Cancer
Research

Center for Child
Health, Behavior and
Development

Center for Clinical and
Translational Research


Center for
Developmental Biology
and Regenerative
Medicine

Center for Global
Infectious Disease
Research

Center for Immunity
and Immunotherapies

Center for Integrative
Brain Research

Center for Respiratory
Biology and
Therapeutics





Growth and Expansion – Cancer Research Program



2020

7 Bench Programs
Associate Center Director
Seattle Therapeutics Division




2021

12 Bench Programs
Center Director/Division Chief
Protein Therapeutics



2022

13 Bench Programs
First Dry Bench Program (PCAR)
Clinical Division
Clinical Research Coordinators



2023

68 Bench/Clinical/Population Research
Programs
Clinical Research Coordinators and Nurses
Clinical Trial Consortiums – COG and PNOG

Center Business Office of Ben Towne



What we do

Grant Support

Proposal Development

Contract/Agreements support including Click data collection and data entry

Bi-monthly Reconciliation Meetings

Post Meeting – email confirmation that meeting took place, action step email communication, CBO commits to addressing all action steps within 3 weeks of the meeting.

Cost Transfers

ETM Editor support

Affiliate Physician Payroll (APP)

Level of Effort (LOE) certification open commitments

Subcontract Management

Invoices

Staff Recruitment - Funding

iLab

Administrative Support

CRC Team

Meeting Support

Audit/Monitoring Visit

Special Guest Visits

Service Now Ticket

Concur Travel

Maintain the CRC Support budget

Faculty

Center Level

Calendar Support

Seminar support

Special Guest Visits

Lab Level

Calendar Support

Service Now Ticket

Capital Equipment

Concur Travel (PI)

Egencia Travel (PI)

Contract/Agreements support including Click data collection and data entry



New PI Lawson requisitioning for lab supplies

Support GCAs with signature routing for Cost Transfers



The tools we use





The Nine C's of Effective Communication: Part 2



By SRAI News posted 01-13-2022 10:53 AM

Clear - It is important to be clear about the purpose of the message you are delivering. The recipient wants to know why they are receiving the message and what you are trying to achieve by delivering it. Secondly, it is key that the content is clear: You should avoid jargon, use plain language, write simple sentence structures and focus on the core points of your message.

Correct - Make sure that both the facts and information you share and language and grammar you use are correct. If your audience spots errors in either, they will be distracted and your credibility reduced.

Complete - Give the recipient all of the information they need to be able to follow your line of reasoning and to reach the same conclusion as you did. The level of detail needed will depend on the situation. In addition, you should make things as easy as possible for your audience. For example, if you are issuing a "call to action", provide explicit guidance on that action. A newsletter in digital format (pdf on a webpage) allows you to insert hyperlinks to more detailed information, which give those wishing to do so access to a complete set of information, while also ensuring that the text can stay on message.

Concrete - Ensure that you are specific and that the logic and messages that you are using fit together, build on each other and support each other. Base your arguments on solid facts and opinions from credible sources and only share irrefutable data to support your argument. When you deal with a new concept, a concrete example can often bring your idea to life, and show relevance to your audience.

Concise - When communicating, it is important to stick to the point and keep your messages short and simple. Do not use 10 words if you can say it with five. Do not repeat your messages. The more you say, the more risk there is of confusion: focus on the key points you want to deliver. KISS: Keep It Simple and Short.

Courteous - You can increase the efficacy of your communication by being polite and showing your audience that you respect them. Your messages should be friendly, professional, considerate, respectful, open and honest. Consider how a sensitive audience will receive your message.

Coherent - Aim for a logical flow and keep the style, tone and language consistent throughout: One final editor!

Consistency - With regards to the structure of the newsletter, stick to the same lay-out and style, and keep the same sections/topics always in the same order. Hence, think long and hard about which sections to include: Will you have regular news/copy for each section?

Creative - Ensure the newsletter is visually appealing. Use white space and brighten things up, by incorporating images and (info)graphics.



Authored by **Floris van der Leest**, Manager, Research Information
King Abdullah University of Science and Technology


The path we take




Proposals, Awards,
Agreements and
Contracts



SCRI Stages of a grant submission



SCRI and Ben Towne Stages of a grant submission








Checklist and Email Example

Application Checklist and Due Dates

PI: Dr. Smith
Sponsor: NIH
RFA: PA-XX-XXX
Sponsor deadline: MM/DD/YYYY XX:XX PM
OSR deadline: MM/DD/YYYY 09:00 AM
CBM deadline: MM/DD/YYYY 09:00 AM
GCA deadline: MM/DD/YYYY 09:00 AM

Link to SF424 Application Guide (Form F)	https://grants.nih.gov/grants/how-to-apply-application-guide/forms-f/fellowship-forms-f.pdf
Attachment Formatting Requirements	1) Separate WORD/PDF document with ½ inch margins 2) No headers and footers 3) In Arial, Helvetica, Palatino Linotype or Georgia font type with font size of 11 or larger.

Due Date	Document	Received	Description	Notes
(2 weeks prior to funding deadline)	Budget	<input type="checkbox"/>		
(2 weeks prior to funding deadline)	Budget Justification	<input type="checkbox"/>	No Page Limit	
(GCA Deadline)	Project Summary/Abstract	<input type="checkbox"/>	30 lines of text	
(GCA Deadline)	Project Narrative	<input type="checkbox"/>	No more than three sentences to describe the relevance of the research to public health.	
(GCA Deadline)	NIH Biosketch for all key personnel	<input type="checkbox"/>	Five-page limit per Biosketch	
(GCA Deadline)	Authentication of Key Biological and/or Chemical Resources	<input type="checkbox"/>	No page limit	
(GCA Deadline)	Facilities and Resources	<input type="checkbox"/>	No page limit	
(GCA Deadline)	Equipment (if applicable)	<input type="checkbox"/>	No page limit	
(GCA Deadline)	Data Sharing Plan	<input type="checkbox"/>	No page limit	
(GCA Deadline)	Letters of Support	<input type="checkbox"/>	No page limit	
(GCA Deadline)	Vertebrate Animals (if applicable)	<input type="checkbox"/>	No page limit	
(GCA Deadline)	Select Agent Research (if applicable)	<input type="checkbox"/>	No page limit	
(GCA Deadline)	Resource Sharing Plan	<input type="checkbox"/>	No page limit	
(GCA Deadline)	Cover Letter (Optional)	<input type="checkbox"/>	One page	
(GCA Deadline)	PHS Assignment Request (optional)	<input type="checkbox"/>		
(3pm-day before CBM Deadline)	Specific Aims	<input type="checkbox"/>	One-page limit	
(3pm-day before CBM Deadline)	Research Strategy	<input type="checkbox"/>	Six-page limit	
(3pm-day before CBM Deadline)	References	<input type="checkbox"/>	No page limit	


Budgets	History	Reviewers	Attachments	Related Projects	Change Log	Reviewer Notes	
Activity						Author	▼ Activity Date
	Added Attachments					Barnes, Nicola	10/16/2023 3:40 PM
	Changes Requested By Department					Hernandez, Maria	10/16/2023 2:18 PM
6 Reviewer Notes Logged.							
	Email sent					Barnes, Nicola	10/16/2023 8:09 AM
Hello Dr. Kalia,							
I wanted to let you know I have submitted your application for CBO Review. I will let you know if there are any edits/questions and when you application is ready to be submitted to OSR.							
Thank you, Nicola Barnes							
	Department Approver Assigned					Barnes, Nicola	10/16/2023 8:06 AM
	Submitted for Department Review					Barnes, Nicola	10/16/2023 8:05 AM




Ardem Patapoutian
@ardemp

R01 application was administratively withdrawn because we cited “Doe et al.” instead of using numerical citations. I understand it was our mistake and appreciate the need to anonymize, but why not check at the time of submission and give us a chance to correct? @NIH @NIHDirector.


10:39 AM · Oct 6, 2023 · 409.4K Views



Ben Towne stages of an agreement submission




Stages of a Clinical Trial submission



The path we take



Proposals, Awards,
Agreements and
Contracts



Portfolio
Management



16


General

PostsFilesAdmin ProjectsPre-AwardBudget ProjectionsJP CP AF NB PP DG LK CW3 more+

Meet

All ActiveFilterListBoardChartsSchedule

Task title	Assigned to	Priority	Due	Bucket ↓
+ Add a task				
<div></div> (Instructions) PI Surname MMM-MMM YYY Recon	<div>0/9</div>			Template
<div></div> Lawlor Sept - Oct 2023 Recon	<div>0/8</div>		11/30	Lawlor (Colie)
<div></div> Lawlor Jul - Aug 2023 Recon	<div>0/8</div>	<div>9/28</div>		Lawlor (Colie)
<div></div> Crotty Budget Projections August - September 2023	<div>0/6</div> <div>WC</div> Willingham, Cynthia			Crotty (Cynthia)
<div></div> Crotty Budget Projections June - July 2023	<div>0/6</div> <div>WC</div> Willingham, Cynthia			Crotty (Cynthia)
<div></div> Crotty Budget Projections April-May 2023	<div>0/6</div> <div>WC</div> Willingham, Cynthia			Crotty (Cynthia)
<div></div> Geddis Nov-Dec 2023 Recon	<div>0/9</div> <div>FA</div> Feng, Annie			Geddis (Feng)
<div></div> Geddis Sept-Oct 2023 Recon	<div>0/9</div> <div>FA</div> Feng, Annie			Geddis (Feng)
<div></div> Gustafson Oct-Nov 2023 Recon	<div>0/9</div> <div>KL</div> Kresl, Lisa		12/20	Gustafson (Lisa)
<div></div> Gustafson Aug-Sept 2023 Recon	<div>0/9</div> <div>KL</div> Kresl, Lisa		10/25	Gustafson (Lisa)
<div></div> Leary May-Jun 2023 Recon	<div>0/9</div>			Leary (Cynthia)
<div></div> PNOC August-September 2023	<div>0/6</div> <div>WC</div> Willingham, Cynthia		10/31	PNOC (Cynthia)
<div></div> Sarthy March-April 2023 Recon	<div>0/9</div>			Sarthy (Patricia)
<div></div> Tarlock Jun-July 2023 Recon	<div>0/9</div>			Tarlock (David)
<div></div> Tarlock Apr-May 2023 Recon	<div>0/9</div>			Tarlock (David)
<div></div> Tarlock Feb-Mar 2023 Recon	<div>0/9</div>			Tarlock (David)
<div></div> COG October-November 2023 Recon	<div>0/1</div> <div>PP</div> Price, Paula		1/2024	COG (Paula)
<div></div> COG August-September 2023 Recon	<div>0/1</div> <div>PP</div> Price, Paula		10/27	COG (Paula)



Principal Investigator Budget Meeting Summary

Seattle Children's Research Institute Policy (SR-01) states that the PI of sponsored research activity must regularly review the relevant aspects of their awards.

Review Period

PI:

Expense Period

Start: 07/01/2023

End: 08/31/2023

Prepared By:

Colie Pilling

Center:

BTCCCR

Budget Meeting Date:

09/27/2023

Accounts Summary

Activity Number	Short Title	Direct Sponsor Name	Funding Type	Project End Date	Activity Status	Award Amount/Revenue Received (Direct)	Actual Expenses to Date (Direct)	% Actual Spent	Projected and Actual Commitments (Direct)	Available Direct Costs (True Subject)	Date Projected Through	Questions or Concerns
24010199	Lawlor Seed Funds	SCRI	Internal	3/30/2045	Active/Open	6,000,000	354,421	16%	480,476	4,565,103	3/30/2024	
24010211	Seed - Effort Support Lawlor	SCRI	Internal	5/31/2030	Active/Open	335,709	207,420	62%	124,880	3,409	3/30/2024	
24070892	IFSC AY24-Lawlor, Elizabeth	SCRI	Internal	6/30/2024	Active/Open	39,005	3,841	10%	35,146	18	6/30/2024	
410380480101	Ewing Sarcoma Fund	1 Million for Anna + Various Gifts	Gift/Endowment	3/30/2045	Active/Open	237,000	114,339	48%	122,660	1	4/28/2024	
410380610101	Sarcoma Science Innovation Fnd	Sam Day Gift + Various Gifts	Gift/Endowment	3/30/2045	Active/Open	233,500	102,326	44%	113,435	17,739	3/30/2024	
419450020101	Lawlor Menin R01	NIH	Federal Prime	3/30/2023	Active/Open	339,606	893,364	95%	46,245	(3)	3/30/2023	
419450090101	CURE Foundation Lawlor	CURE Childhood Cancer	Foundation Prime	3/30/2023	Active/Open	141,802	126,256	89%	15,076	470	3/30/2023	
419450100101	CURE_Lawlor_T2C	CURE Childhood Cancer	Foundation Prime	6/30/2025	Active/Open	150,000	4,872	3%	131,616	13,512	6/30/2024	
24010317	PORT T32 Effort Support Lawlor	SCRI	Internal	6/30/2024	Active/Open	45,757	24,630	54%	21,127	0	6/30/2024	
41038080101	Sarcoma Research Fund	SCRI	Internal	3/30/2045	Active/Open	138,009	561	0%	-	137,448	3/30/2045	
Activity Number	Short Title	Direct Sponsor Name	Funding Type	Project End Date	Activity Status	Award Amount/Revenue Received (Direct)	Actual Expenses to Date (Direct)	% Actual Spent	Projected and Actual Commitments (Direct)	Available Direct Costs (True Subject)	Date Projected Through	Questions or Concerns

Recent Submissions/Applications

Submitted (MM/Y)	Short Title	Sponsor	CLICK #	Additional Information (collaborators, subawards, etc.)
2/13/2023	Lawlor R21 Ewing Sarcoma	NIH/PA-22-216	FP1852_res1	PI: Lawlor, Co-I: Mayer, Olson, Sarthy. Resubmission
6/5/2023	Lawlor R01 (new)	NIH	R01	

Upcoming Submissions/Applications

Due Date	Short Title	Sponsor	Grant Type	Additional Information (collaborators, subawards, etc.)
10/20/2023	Cookies for Kids	Cookies for Kids		PI: Lawlor 3%, Staff: Katie Bruan 40% (start 1/1/24 - 3 years)
2/1/2024	PA-20-185	NIH	R01	sub with pittsburgh childrens
3/1/2024	R01-A1	NIH		sub with FHCC
3/1/2024	ALS Innovation Grant			Pending Lol acceptance

Upcoming Progress Reports/Milestones

Due Date	Short Title	LAN	Reporting Requirement Details

Additional Notes/Comments

Planned Capital Purchases over \$10,000 on federal funds



Version 4.2

Activity #: 419450020101
PI:
Short Title: Lawlor Menhir R01 Transfer
Start End: 6/1/2020 9/30/2023

Proposal #: PT-20-0508
Award Type: Grant
Sponsor #: R01 CA2181168
Sponsor: #1252 National Cancer Institute
Staff Fringe: 29.3%
Date of Reconciliation: 9/25/2023

		Budget Start Date:	6/1/2020	Unobligated	6/1/2021	6/1/2022	Total	Reconciled	Subtotal	Encumbered	Calculated	Cost Xfers /	Total	Balance
		Budget End Date:	5/31/2021	Balance	5/31/2022	9/30/2023	Budget	through		Commitments	Projected	Adjustments	Expenses	
Account	Account Category		Year 1		Year 2	Year 3		8/31/2023		in Lawson	Expenses			
Category	Description		New		New	New								
70000	Salary		85,180	-	91,674	87,006	263,860	298,924.95	(35,064.95)	-	17,120.94	-	316,045.89	(52,185.89)
71000	Fringe		24,106	-	29,244	25,493	78,843	89,893.15	(11,050.15)	-	5,016.44	-	94,909.59	(16,066.59)
73300	Lab Supplies		14,167	23,910	23,997	28,064	90,138	80,055.26	10,082.74	2,611.86	1,600.00	-	84,267.12	5,870.88
74900	Office Supplies							135.22	(135.22)	-		-	135.22	(135.22)
74940	Freight/Delivery		-	-	-	-	-	2,039.20	(2,039.20)	-		-	2,039.20	(2,039.20)
76000	Repair and Maint Serv		-	-	-	-	-	3,324.59	(3,324.59)	-		-	3,324.59	(3,324.59)
76120	Affiliate Purchased Services		73,336	-	74,140	75,288	222,764	248,265.94	(25,501.94)	-	6,500.87	-	254,766.81	(32,002.81)
76590	Consort <\$25K		25,000	-	-	-	25,000	25,000.00	-	-	-	-	25,000.00	-
76592	Consort >\$25K		43,876	-	38,360	-	82,236	82,236.00	-	-	-	-	82,236.00	-
76900	Other Purchased Services		-	-	28,731	29,000	57,731	37,717.25	20,013.75	13,395.38	-	-	51,112.63	6,618.37
76950	Internal Purchased Services		42,124	23,910	8,000	24,000	98,034	10,654.72	87,379.28	-	-	-	10,654.72	87,379.28
79200	Licenses & Taxes		-	-	-	-	-	800.00	(800.00)	-		-	800.00	(800.00)
79800	Other Miscellaneous Expense		12,000	-	4,000	-	16,000	14,317.94	1,682.06	-	-	-	14,317.94	1,682.06
79858	Other Travel		2,500	-	-	2,500	5,000	-	5,000.00	-	-	-	-	5,000.00
79990	Otr Exp CT		-	-	-	-	-	-	-	-	-	-	-	-
Total Direct Costs			322,289	47,820	298,146	271,351	939,606	893,364.22	46,241.78	16,007.24	30,238.24	-	939,609.70	(3.70)
79900 F&A			239,435	41,124	223,416	233,363	737,338	696,882.29	40,455.85	13,766.23	26,004.89	-	736,653.40	684.74
TOTAL COSTS			561,724	88,944	521,562	504,714	1,676,944	1,590,246.51	86,697.63	29,773.47	56,243.13	-	1,676,263.10	681.04

Notes

- 09/25/2023 Projected Expenses:
- PI salary through Sept 2023
 - Staff salary through Sept 2023
 - Lab Supplies and Vivarium through Sept 2023
 - Genomic Core and Sequencing through Sept 2023
 - Publication: \$4,000



Estimated Carryover Percentage
0.0%





Review Period			
Coortium:	COG CT Overview	Prepared By:	Paula Price
Expense Period Start:	06/01/2023	Center:	BTCCCR
Expense Period End:	07/31/2023	Budget Meeting Date:	08/23/2023

COG Master Agreements						
PI	Click #	Short Title	Direct Sponsor Name	Date FEA	Status	Questions or Concerns
	MA00000041	COG Foundation Master Agreement	Children's Oncology Group Foundation	08/09/2022	Active	
	MA00000008	COG Master Agreement for Industry Funding Sources	Public Health Institute (PHI)	05/15/2021	Active	
	MA21-0157-AGR001	Master Agreement: Non-Industry	Public Health Institute (PHI)	03/01/2021	Active	
	MA00000003	COG Lilly Campaign Master Agreement	CHOP	10/26/2021	Active	
	PT-12-012	COG Industry Master	CHOP			
	PT-12-083	COG Non-Industry Master	CHOP			

Accounts Summary													
PI	Activity Number	Short Title	Type	Direct Sponsor Name	Master Agreement	Project End Date	Activity Status	Total Revenue Received to Date	Total Expenses	% Actual	Total Projected	Date Projected	Comments or Questions
Leary, Sarah	415870450201	COG CT ACN21831 Astra2 SuppPCR	CT	PHI (AstraZeneca)	PHI Industry (MA000000008)	07/14/2032	Active/Open	\$0.00	\$0.00	#DIV/0!	0.00	07/31/2023	Internal amendment processed to extend end date.
Leary, Sarah	415870404301	COG CT AAML1921-Pfizer	CT	PHI (Pfizer)	PHI Industry (MA000000008)	06/30/2030	Active/Open	\$8,500.00	\$4,360.93	51.31%	4,139.07	07/31/2023	Fully-funded industry study; internal amendment processed to extend end date.
Leary, Sarah	415870430201	COG CT AAML1921-Pfizer	CT	PHI (Pfizer)	PHI Industry (MA000000008)	06/30/2025	In Closeout	\$0.00	\$1,364.53	#DIV/0!	(1,364.53)	07/31/2023	Cost transfers in process to transfer expenses to year 1 LAN (row above); no need for new LAN w/sponsor change.
Leary, Sarah	415870500101	COG Banking Supplement	CT	CHOP (NIH)	CHOP Non-Industry (PT-12-083)	2/28/2021	In Closeout	\$14,000.00	\$0.00	0.00%	14,000.00	02/28/2021	Poals determining where/ff we can transfer revenue
Leary, Sarah	415870510101	COG ANBL 1221 Supplement	CT	CHOP	CHOP Industry (PT-12-07)	8/31/2021	In Closeout	\$1,575.00	\$0.00	0.00%	1,575.00	08/31/2021	Poals determining where/ff we can transfer revenue
Leary, Sarah	415870520101	COG Antopy Supplement	CT	CHOP (NIH)	CHOP Non-Industry (PT-12-083)	2/28/2021	In Closeout	\$50,000.00	\$0.00	0.00%	50,000.00	02/28/2021	Poals determining where/ff we can transfer revenue
Leary, Sarah	415870540101	COG CT AOST2121 OS Therapies	CT	PHI (OS Therapies)	PHI Industry (MA000000008)	03/08/2031	Active/Open	\$26,500.00	\$53,843.56	203.21%	(27,343.56)	07/31/2023	Fully-funded industry study. Internal amendment processed to update sponsor to PHI and extend end date.
Leary, Sarah	415870550101	COG Study: AAML1831 - A Collab	CT	CHOP	CHOP Industry (PT-12-07)	12/31/2022	Closed	\$15,000.00	\$15,000.00	100.00%	0.00	12/31/2022	
Leary, Sarah	415870580101	COG CT NCTN PCR Non-Industry	CT	PHI (NIH)	PHI Non-Industry (MA21-05T-AGR001)	02/28/2025	Active/Open	\$378,040.00	\$4,083,672.88	1080.22%	(3,705,632.88)	07/31/2023	Additional cost transfers in process from Dr. Hawkins' LAN; transfers are near complete.
Leary, Sarah	415870590101	COG CT AALL1921 Supplement	CT	CHOP (SBF)	CHOP Non-Industry (PT-12-083)	02/15/2023	In Closeout	\$600.00	\$0.00	0.00%	600.00	02/15/2023	
Leary, Sarah	415870600101	COG CT ANBL1531 ADJ (JDL ANBL1531_Site)	CT	PHI (Jubilant Drugimags)	PHI Industry (MA000000008)	12/31/2025	Active/Open	\$0.00	\$0.00	#DIV/0!	0.00	07/31/2023	
Leary, Sarah	415870610101	COG APEC1621SC QuedV	CT	CHOP (NIH)	CHOP Non-Industry (PT-12-083)	6/30/2023	Active/Open	\$2,000.00	\$0.00	0.00%	2,000.00	07/31/2023	
Leary, Sarah	415870620101	COG ACN31833 PETTF Supplement	CT	CHOP	CHOP Non-Industry (PT-12-083)	2/28/2022	In Closeout	\$3,750.00	\$0.00	0.00%	3,750.00	02/28/2022	Poals determining where/ff we can transfer revenue
Leary, Sarah	415870620201	COG CT ACN1633 PETTF Supplement PCR	CT	PHI (PETTF)	PHI Industry (MA000000008)	06/30/2027	Active/Open	\$0.00	\$0.00	#DIV/0!	0.00	07/31/2023	
Leary, Sarah	415870640101	COG CT AAML1931 JazzActallSupp	CT	PHI (Jazz Pharmaceuticals & Actallis Pharma)	PHI Industry (MA000000008)	2/28/2025	Active/Open	\$0.00	\$8,357.88	#DIV/0!	(8,357.88)	07/31/2023	
Leary, Sarah	415870650101	COG CT NCORP PCR Non-Industry	CT	PHI (NIH)	PHI Non-Industry (MA21-05T-AGR001)	7/31/2025	Active/Open	\$64,000.00	\$0.00	0.05%	63,370.00	07/31/2023	
Leary, Sarah	415870660101	COG CT AALL1331 Amgen Supp	CT	PHI (Amgen)	PHI Industry (MA000000008)	2/28/2025	Active/Open	\$0.00	\$0.00	#DIV/0!	0.00	07/31/2023	Amendment 1 processed
Leary, Sarah	415870700101	COG CT ANBL1531 Pfizer	CT	PHI (Pfizer)	PHI Industry (MA000000008)	12/31/2027	Active/Open	\$0.00	\$1,916.30	#DIV/0!	(1,916.30)	07/31/2023	
Leary, Sarah	415870710101	COG CT ADVL1921 Pfizer	CT	CHOP (Pfizer)	CHOP Industry (PT-12-07)	2/28/2022	Closed	\$0.00	\$0.00	#DIV/0!	0.00	02/28/2022	New LAN under Dr. Turlock
Leary, Sarah	415870750101	COG CT ALTE2031	CT	CHOP (NIH)	CHOP Non-Industry (PT-12-083)	8/31/2024	Active/Open	\$1,800.00	\$30.00	1.67%	1,770.00	07/31/2023	
				PHI (NIH)	PHI Non-Industry (MA21-05T-AGR001)								


Navin	417620270101	COG CT ADVL2021B JVO2 Lilly	CT	CHOP (Eli Lilly)
	Overview	Current Budget Summary	Current Expense Summary	Current Revenue Summary
 Internal  Accessibility: Investigate				



The path we take



Proposals, Awards,
Agreements and
Contracts



Portfolio
Management



Programmatic and
Clinical Staff
Management



A	B	C	D	DN	DO	DP	DQ	DR	DS	DT	DU	DV	DW
Center:	BTCCCR												
AY 2024 (pay period end dates)													
LAN	Short Title	Project Period End Date	Notes	10/29/23	11/12/23	11/26/23	12/10/23	12/24/23	01/07/24	01/21/24	02/04/24	02/18/24	03/03/24
	Sarcoma Research Fund			10.0%	10.0%	10.0%	10.0%	10.0%	10.0%	10.0%	10.0%	10.0%	10.0%
			Total FTE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Miyaki, Aya	Res Scientist II	Rate:	31.48										
EID: <div></div>		FTE:	1.00										
24010199	Lawlor Seed	09/30/45											
410380480101	Ewing Sarcoma Gift	09/30/45		100.0%	100.0%	100.0%	100.0%	100.0%	75.0%	75.0%	75.0%	75.0%	75.0%
419450060201	SU2C DFCI Lawlor	12/31/23											
419450090101	CURE Foundation Lawlor	09/30/23											
	Ganapathi Hyundai Hope	12/31/25							25.00%	25.00%	25.00%	25.00%	25.00%
			Total FTE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Wrenn, Emma	Post Doc Fellow	Rate:	\$31.48										
EID: <div></div>		FTE:	1.00										
24010199	Lawlor Seed	09/30/45											
410380480101	Ewing Sarcoma Gift	09/30/45		70.0%	70.0%	70.0%	70.0%	70.0%					
419450060201	SU2C DFCI Lawlor	12/31/22											
	Wrenn AACR	06/30/23											
419450100101	CURE_Lawlor_T2C	06/30/25		30.0%	30.0%	30.0%	30.0%	30.0%					
TBD	WRF Phase I								100%	100%	100%	100%	100%
			Total FTE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Tu, Darleen	Post Doc Fellow (OAC)	Rate:	\$29.56										
EID: <div></div>		FTE:	0.250										
410380480101	Ewing Sarcoma Gift	09/30/45		100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
			Total FTE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

<input type="checkbox"/>	Code	Sort Order^	Effective Date	Expiration Date
<input type="checkbox"/>	100%AldarraChair	<div><div></div>1</div>	07/10/2023	>
<input type="checkbox"/>	Seed Loh	<div><div></div>2</div>	07/10/2023	>
<input type="checkbox"/>	AndyHill Infrast	<div><div></div>3</div>	07/24/2023	>



The path we take



Proposals, Awards,
Agreements and
Contracts



Portfolio
Management




Programmatic and
Clinical Staff
Management



Moving from
Reactive to
Proactive





Ben Towne Center

Business Office



Maria Hernandez
Director



Paula Price (GA)
Sr. Grant &
Contract
Administrator



Nicola Barnes
Business Manager



Kris Rushing
Executive
Assistant for Dr.
Loh




Lisa Kresl
Grant & Contract
Coordinator



Colie Pilling
Grant & Contract
Administrator



Patricia May-
Archuleta (FL)
Grant & Contract
Administrator



Noelle Matthews
Administrative
Assistant Sr.



Kat Reigle
Administrative
Assistant Sr.



Caitlin Wolf
Grant & Contract
Coordinator



Danielle
Gilmore (TX)
Grant & Contract
Administrator



Cynthia
Willingham (GA)
Grant & Contract
Administrator



Andrea
Abercrombie
Administrative
Assistant Sr.



Angela Bach
Administrative
Assistant Sr.



Annie Feng
Grant & Contract
Administrator



David
Fernandez (FL)
Grant & Contract
Administrator

Thank you!!!



Seattle Children's[®]
HOSPITAL • RESEARCH • FOUNDATION

Hope. Care. Cure.